Buy
Sell
Share Name Share Symbol Market Type Share ISIN Share Description
Ip Group Plc LSE:IPO London Ordinary Share GB00B128J450 ORD 2P
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  -0.20 -0.23% 87.50 87.80 88.00 88.50 84.90 88.50 1,708,724 16:35:08
Industry Sector Turnover (m) Profit (m) EPS - Basic PE Ratio Market Cap (m)
General Financial 0.0 -78.8 -7.1 - 930

Ip Share Discussion Threads

Showing 2026 to 2046 of 2150 messages
Chat Pages: 86  85  84  83  82  81  80  79  78  77  76  75  Older
DateSubjectAuthorDiscuss
13/10/2020
10:17
Frustrating that IPO not participating in ONT fundraisings and allowing the stake to be diluted. Now down to 15%. Unless of course there is a plan to acquire a sizeable tranche from Invesco/Lansdowne
wetpantz
13/10/2020
06:44
That ok bamboo2 yours looks better.Nice contract value and interesting website,may use it for future reference.
riddlerone
13/10/2020
06:36
riddler, Sorry I didn't see you had already posted!
bamboo2
13/10/2020
06:32
Https://ted.europa.eu/udl?uri=TED:NOTICE:473179-2020:TEXT:EN:HTML&src=0 A very decent sized order for ONT
bamboo2
13/10/2020
06:31
IP Group PLC 13 October 2020 FOR RELEASE ON 13 October 2020 IP Group plc - Portfolio company Oxford Nanopore Technologies announces GBP84.4m of additional funding IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, notes that its portfolio company Oxford Nanopore Technologies Ltd ("Oxford Nanopore" or "the Company") has announced that it has raised an additional GBP84.4 million of new capital from existing and new investors including International Holdings Company (IHC) and RPMI Railpen. The funds will be used to support the rapid acceleration of Oxford Nanopore's commercial and manufacturing operations as well as ongoing innovation in the field of nanopore technology. The round takes the amount raised this year by Oxford Nanopore to GBP162.1 million, following fund raisings in January and May of GBP29.3 million and GBP48.4 million respectively. Following the capital raise, IP Group has a 15.0% undiluted beneficial stake in Oxford Nanopore, valued at GBP257.7 million. The directors will review the carrying value of Oxford Nanopore, as usual, as part of the Group's Annual Results for 2020 in light of this funding round and all other relevant information. Last week, Oxford Nanopore announced that its LamPORE test is now CE marked for in vitro diagnostic use for the detection of the SARS-CoV-2 virus that causes COVID-19, using its GridION device. Its LamPORE test is now in the process of initial rollouts in the UK, Germany, Switzerland and the United Arab Emirates. The Company previously announced that it had partnered with the UK's Department of Health and Social Care with an initial order of 450,000 LamPORE SARS-CoV-2 tests and the potential to increase to millions of tests per month as indicated by the recent publication of a contract award notice of GBP112.6m on the TED (Tenders Electronic Daily) website. Further regulatory approvals are being pursued in other countries, including Emergency Use Authorisation in the United States, and with its partner G42 in the United Arab Emirates.
bamboo2
12/10/2020
08:14
Bamboo2 - "because the announcement was made mid morning, some will have missed it completely. Others will miss the significance, as IPO is a holding company. It also could be that the market views this news as already 'in the price'." No move in share price this morning effectively rules out the first 2 above. Also, with regard to it being already in the sp, when did the share price reflect this? I don't believe it did at all. There remains another alternative, i.e. persistent selling into any perceived rise. I agree with you about the prospects for ONT. But in my view there are far more "next significant events" to happen before the development of testing using mobile telephony.
benchmark
10/10/2020
14:01
DVRG are steps ahead on your last comment: 'personal testing using a mobile phone'.
empoggio
10/10/2020
11:28
Benchmark, because the announcement was made mid morning, some will have missed it completely. Others will miss the significance, as IPO is a holding company. It also could be that the market views this news as already 'in the price'. Undoubtedly, the news will result in a huge increase in the size of the market for ONT. As a result of this ONT kit will one way or another find its way into every single clinical pathology lab in the world. The next significant events for ONT will involve a broadening of the diagnosis side, and the advent of personal testing using a mobile phone. I am quite excited by the potential for ONT.
bamboo2
10/10/2020
11:09
Thanks bamboo. Useful background info on invesco etc.
p1nkfish
10/10/2020
09:43
Bamboo - thank you for taking the time to reply with that helpful information. With the announcement that ONT obtained the CE mark for the GridIon & MinIon systems, one would have thought/hoped that it would have been reflected in the IPO share price yesterday afternoon. The fact that it wasn't suggests measured selling into any perceived rise?
benchmark
10/10/2020
08:36
Benchmark, for all their faults, Invesco have been good at fulfilling the obligation to file an rns when they have crossed notifiable limits. The total holding is currently 13.49%, and this is unchanged. Any transactions are normally signalled the following day, so in theory we could get an RNS on Monday. The redemption problems at Invesco exist with the UK Equity High Income Fund. This holds a number of quoted and unquoted companies, whose valuations continue to be adversely affected by the Woodford firesale, and other factors. One of the unquoted's they have is ONT. There are at least three interested potential buyers for ONT [Tencent and others] with cash, but afaik no deal has yet been done. I guess that Invesco would want to package up any deal involving ONT, with a load of less desirable stock. Other than the top ten holdings in Invesco's fund, which are published monthly, we have to wait for an end of year report to find out how the holdings have changed.
bamboo2
10/10/2020
07:27
Does anyone know how much of Invesco's 13.5% stake has been sold into the market at this stage? Obviously, it is still above 5%, otherwise we would have had an RNS
benchmark
09/10/2020
08:06
Latest ONT vid on twitter suggesting that production is ramping up in expectation of increase in orders for Lampore CV19 test Https://twitter.com/i/status/1314144456422162432
bamboo2
07/10/2020
10:29
Just wondering what it will take to get this to breakout from its 80p ceiling. Clearly big seller (Invesco?) happy to take that for its shares all day long.I am not a fan of share buybacks but this is one situation where it is warranted.
rogerrail
07/10/2020
07:15
Hi p1nk, yes. They keep the co. although it will have reduced value. If future products are a success, then there will be extra payments. We are still awaiting the ONT CE mark! Now would be a good time to get their skates on.
bamboo2
07/10/2020
07:13
With that much cash they won't be looking to fund small fry as they would never manage the portfolio. It's probably ideas looking for 10M+ & real game changers/moonshots. A re-orientation of the portfolio is possible. What do they know that the martket is unaware of that warrants such a cash pile now?
p1nkfish
07/10/2020
07:06
They have some decent fire power ready to allocate. Where & when?
p1nkfish
07/10/2020
07:05
They keep their holding bamboo, the upside is just for the product sale, not sale of the company?
p1nkfish
07/10/2020
06:48
IP Group receives £16,275,000+ for the co. which was valued at £9,000,000 Half year realisations were at £113.7m Plus additional in July 2020 at £54.4m Plus Enterprise at £16.275m YTD realisation of £184.375m Total cash now approx £291m MCAP £843.5m
bamboo2
07/10/2020
06:37
IP Group plc - Portfolio company Enterprise Therapeutics' TMEM16A potentiator program for treatment of cystic fibrosis & other respiratory diseases acquired by Roche -- IP Group's cash realisations for the year now total GBP183.9m IP Group plc (LSE: IPO) ("IP Group" or "the Group"), the developer of intellectual property-based businesses, is delighted to note that portfolio company Enterprise Therapeutics Ltd ("Enterprise" or "the Company") has announced that its novel TMEM16A potentiator portfolio has been acquired by Roche and will be developed by Genentech, a member of the Roche Group. In connection with the transaction, Enterprise's shareholders received an upfront payment of GBP75 million, and are eligible to receive additional contingent payments, to be made based on the achievement of certain predetermined milestones. As a result of this transaction, IP Group's cash realisations for the year to date now total GBP183.9 million, 2.3 times greater than the GBP79.5 million recorded for the whole of 2019. Following completion of the transaction, the Group has an undiluted beneficial shareholding of 21.7% in Enterprise. At 30 June 2020, the Group's shareholding in Enterprise was valued at GBP9.0 million. The Group's directors anticipate the transaction will result in a fair value gain and are currently reviewing the carrying value of Enterprise, which will be confirmed no later than the 2020 Annual Results. Enterprise is a biopharmaceutical company dedicated to the discovery and development of novel therapies to improve the lives of patients suffering with respiratory disease. The TMEM16A portfolio includes ETD002, which recently entered Phase 1 trials, and is focused toward treating all people with cystic fibrosis (CF) with potential to benefit people with other severe respiratory diseases characterised by excessive mucus congestion. Following acquisition of the TMEM16A portfolio, Enterprise will continue to develop its remaining lead respiratory program, the ENaC blocker ETD001.
bamboo2
06/10/2020
07:24
Good chance you are right bambooo.
p1nkfish
Chat Pages: 86  85  84  83  82  81  80  79  78  77  76  75  Older
ADVFN Advertorial
Your Recent History
LSE
IPO
Ip
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.

By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

P: V: D:20201127 03:28:08